(126 days)
Yes
The intended use and device description mention an "arrhythmia detection algorithm" and "automatically detected cardiac events," which strongly suggests the use of an algorithm to analyze ECG data for patterns indicative of arrhythmias. While not explicitly stating "AI" or "ML," this type of automated detection based on complex physiological signals is a common application of these technologies in medical devices.
No
The device is described as being for "diagnostic evaluation" and for "measure, record, store and/or remotely transfer the Electrocardiogram (ECG)", which are diagnostic functions, not therapeutic ones.
Yes
The "Intended Use / Indications for Use" section explicitly states, "The TeleSense device is intended for diagnostic evaluation of patients who experience transient symptoms or asymptomatic events that may suggest cardiac arrhythmia." It also mentions that the device "automatically records events triggered by an arrhythmia detection algorithm" and "transmits the recorded event activity associated with these symptoms for review by a licensed physician," all of which are functions associated with diagnosis.
No
The device description explicitly states it is a "battery powered portable device" and mentions "electronic platform," indicating it includes hardware components for ECG data collection, recording, and transmission.
Based on the provided text, the TeleSense device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze samples taken from the human body (like blood, urine, tissue) in vitro (outside the body). The TeleSense device measures and records the Electrocardiogram (ECG), which is an electrical signal generated by the heart and measured non-invasively on the surface of the body. This is a physiological measurement, not an analysis of a biological sample.
- The intended use describes monitoring and recording ECG data for diagnostic evaluation of cardiac arrhythmias. This involves capturing electrical activity of the heart, not analyzing the composition or properties of a biological sample.
The TeleSense is a medical device used for physiological monitoring and recording, specifically of the heart's electrical activity. It falls under the category of cardiac monitors or recorders, not IVDs.
No
The provided text does not contain any explicit statement that the FDA has reviewed, approved, or cleared a PCCP for this specific device. The 'Control Plan Authorized (PCCP) and relevant text' section is marked 'Not Found'.
Intended Use / Indications for Use
The TeleSense device is intended for diagnostic evaluation of patients who experience transient symptoms or asymptomatic events that may suggest cardiac arrhythmia. The device continuously monitors and records the data, automatically records events triggered by an arrhythmia detection algorithm or manually by the patient, and automatically transmits the recorded event activity associated with these symptoms for review by a licensed physician.
The TeleSense is a battery powered device to be used to measure, record, store and/or remotely transfer the Electrocardiogram (ECG) noninvasively in mobile patients. The available data transfer methods are USB and Wi-Fi. TeleSense is not limited to certain patient groups or pathologies; however, the TeleSense is not intended for pediatric use. Examples of applications are:
- Cardiology
- Pulmonary Care
- Home Care
- General Practitioners
Product codes (comma separated list FDA assigned to the subject device)
DSI, DRG
Device Description
The basic operation of the TeleSense platform is to collect and store multiple channels of ECG data. The TeleSense platform was developed to be used as basic platform for 4 different variants on the product, hereafter called "modes". The electronic platform of the different versions is identical but the different modes have some features added or removed from the electronic platform. The differences are related to features. All versions have the same intended use, intended users and intended environment. The different versions are described below.
-
Basic Mode (Remote cardiac monitor)
TeleSense’s Basic Mode is the basic version of the product. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer the Electrocardiogram (ECG) in mobile patients, as well as cardiac event data. The device only uses non-invasive sensors. The available integrated data transfer methods are USB and Wi-Fi. -
Event Mode
TeleSense’s Event Mode operates as a traditional event recorder. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer manually indicated or automatically detected cardiac events in mobile patients. The device only uses non-invasive sensors. The available integrated data transfer methods are Wi-Fi and USB. -
Holter Mode
TeleSense’s Holter Mode operates as a traditional Holter recorder. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer the electrocardiogram (ECG) in mobile patients. The device only uses non-invasive sensors. The available integrated data transfer methods are Wi-Fi and USB. In this version, there is no automatic cardiac event detection.
Significant Physical and Performance Characteristics
Design and Performance:
-Configurable to record and transmit encrypted patient ECG and Event data
-Transmits data over Wi-Fi
-Includes a status interface to give feedback to the user
-Includes a manual event button for marking manual events
-Device includes configurable automatic event detection
-Patient is connected to device with noninvasive skin-surface ECG electrodes
-ECG and event data is sent to a remote server for review or on-demand streaming of ECG
Materials:
-Device housing made from Ultem HU1000 plastic or equivalent, which meets requirements for flammability and biocompatibility
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
TeleSense is not intended for pediatric use.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Appropriate testing was conducted in accordance with established design control procedures and regulatory guidance documents. The TeleSense meets the safety, mechanical, electrical, and performance requirements of IEC 60601-1, the emissions requirements of IEC 60601-1-2:2007, and the safety, electrical, and performance requirements of IEC 60601-2-47 Part2.
The internal tests conducted were intended to test the performance of the device and included simulated normal ECG signals and simulated paced ECG signal tests. Data recorded was loaded and analyzed in the HolterCare(K042463) and EventCare (K061780) software. In all tests, the TeleSense produced consistent and acceptable results.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, which is a traditional symbol of medicine.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 12, 2014
Scottcare Corporation Snehraj Merchant Vice President, Engineering 4791 West 150th St. Cleveland, Ohio 44135
Re: K142180 Trade/Device Name: TeleSense Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector And Alarm (Including ST-Segment Measurement And Alarm) Regulatory Class: Class II Product Code: DSI, DRG Dated: November 7, 2014 Received: November 10, 2014
Dear Snehraj Merchant,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Melissa A. Torres -S
For
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
Device Name: TeleSense (K142180)
The TeleSense device is intended for diagnostic evaluation of patients who experience transient symptoms or asymptomatic events that may suggest cardiac arrhythmia. The device continuously monitors and records the data, automatically records events triggered by an arrhythmia detection algorithm or manually by the patient, and automatically transmits the recorded event activity associated with these symptoms for review by a licensed physician.
The TeleSense is a battery powered device to be used to measure, record, store and/or remotely transfer the Electrocardiogram (ECG) noninvasively in mobile patients. The available data transfer methods are USB and Wi-Fi. TeleSense is not limited to certain patient groups or pathologies; however, the TeleSense is not intended for pediatric use. Examples of applications are:
- Cardiology
- Pulmonary Care
- Home Care
- General Practitioners
Contraindications:
a. Patients with potentially life-threatening arrhythmias who require inpatient monitoring.
- b. Patients who the attending physician thinks should be hospitalized.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page of
3
Image /page/3/Picture/0 description: The image shows the logo for ScottCare. The text "ScottCare" is in a large, bold, sans-serif font. Below the name is the text "cardiovascular solutions" in a smaller, lighter font. There is a thin line above the text "cardiovascular solutions".
510(K) SUMMARY
This summary of 510(k) safety and effectiveness information is being supplied in accordance with the requirements of the SMDA of 1990 and 21 CFR 807.92
The assigned 510(k) number is
| Date: | July 29, 2014 |
|---|---|
| Submitted by: | ScottCare Corporation |
| Registration No: 1527715 | |
| 4791 West 150th Street | |
| Cleveland, OH 44135 | |
| Contact Person: | Snehraj Merchant |
| ScottCare Corporation | |
| 4791 West 150th Street | |
| Cleveland, OH 44135 | |
| Manufacturing Site: | ScottCare Corporation |
| Registration No: 1527715 | |
| 4791 West 150th Street | |
| Cleveland, OH 44135 | |
| Trade Name: | TeleSense |
| Common Name: | Detector and Alarm, Arrhythmia |
| Classification: | 870.1025 |
| Arrhythmia detector and alarm (including ST-segment measurement | |
| and alarm) | |
| Product Code: | DSI |
| Subsequent | |
| Product Code: | DRG |
| Legally Marketed | |
| Predicate Device(s): | ScottCare TeleSentry Wireless Ambulatory ECG Arrythmia Monitor, |
A Scott Fetzer, Berkshire Hathaway Company
4
Image /page/4/Picture/0 description: The image shows the logo for ScottCare cardiovascular solutions. The text "ScottCare" is in a large, bold font. Below that, in a smaller font, is the text "cardiovascular solutions."
Device Description:
The basic operation of the TeleSense platform is to collect and store multiple channels of ECG data. The TeleSense platform was developed to be used as basic platform for 4 different variants on the product, hereafter called "modes". The electronic platform of the different versions is identical but the different modes have some features added or removed from the electronic platform. The differences are related to features. All versions have the same intended use, intended users and intended environment. The different versions are described below.
1. Basic Mode (Remote cardiac monitor)
TeleSense's Basic Mode is the basic version of the product. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer the Electrocardiogram (ECG) in mobile patients, as well as cardiac event data. The device only uses non-invasive sensors. The available integrated data transfer methods are USB and Wi-Fi.
2. Event Mode
TeleSense's Event Mode operates as a traditional event recorder. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer manually indicated or automatically detected cardiac events in mobile patients. The device only uses non-invasive sensors. The available integrated data transfer methods are Wi-Fi and USB.
3. Holter Mode
TeleSense's Holter Mode operates as a traditional Holter recorder. It is a battery powered portable device to be used to collect, record, store and/or remotely transfer the electrocardiogram (ECG) in mobile patients. The device only uses non-invasive sensors. The available integrated data transfer methods are Wi-Fi and USB. In this version, there is no automatic cardiac event detection.
Significant Physical and Performance Characteristics
Design and Performance:
- -Configurable to record and transmit encrypted patient ECG and Event data
- Transmits data over Wi-Fi -
- Includes a status interface to give feedback to the user -
- -Includes a manual event button for marking manual events
- Device includes configurable automatic event detection -
- Patient is connected to device with noninvasive skin-surface ECG electrodes -
- ECG and event data is sent to a remote server for review or on-demand streaming of ECG -
Materials:
A Scott Fetzer, Berkshire Hathaway Company
5
Image /page/5/Picture/0 description: The image shows the logo for ScottCare cardiovascular solutions. The text "ScottCare" is in a large, bold font. Below that, in a smaller font, is the text "cardiovascular solutions."
- -Device housing made from Ultem HU1000 plastic or equivalent, which meets requirements for flammability and biocompatibility
Indications for Use:
The TeleSense device is intended for diagnostic evaluation of patients who experience transient symptoms or asymptomatic events that may suggest cardiac arrhythmia. The device continuously monitors and records the data, automatically records events triggered by an arrhythmia detection algorithm or manually by the patient, and automatically transmits the recorded event activity associated with these symptoms for review by a licensed physician.
The TeleSense is a battery powered device to be used to measure, record, store and/or remotely transfer the Electrocardiogram (ECG) noninvasively in mobile patients. The available data transfer methods are USB and Wi-Fi. TeleSense is not limited to certain patient groups or pathologies; however, the TeleSense is not intended for pediatric use. Examples of applications are:
- Cardiology
- Pulmonary Care
- Home Care
- General Practitioners
Contraindications:
- a. Patients with potentially life-threatening arrhythmias who require inpatient monitoring.
- b. Patients who the attending physician thinks should be hospitalized.
A Scott Fetzer, Berkshire Hathaway Company
6
Image /page/6/Picture/0 description: The image shows the logo for ScottCare. The text "ScottCare" is in a large, bold font. Below the name is the text "cardiovascular solutions" in a smaller font. There is a thin line above the text "cardiovascular solutions".
Substantial Equivalence:
| Features | Predicate Device: ScottCare TeleSentry
K092947 | New Device: TeleSense* |
|-------------------------------------|---------------------------------------------------|------------------------|
| 510(k) Number | K092947 | K142180 |
| Date Cleared | February 26,2010 | TBD |
| Patient Cable 3-lead | Yes | Yes |
| Patient Cable 5-lead | Yes | Yes |
| Patient Cable 12-lead | Yes | Noi |
| Lead Off Detection | Yes | Yes |
| Channel Recording | 3, 5 and 12 | 3ii |
| Monitoring Mode | Continuous | Continuous |
| Data Transmission | Radio Frequency(RF) | Radio Frequency(RF) |
| Recording Button | Yes | Yes |
| Unintentional Erase data Protection | Yes | Yes |
| Power Loss Data Protection | Yes | Yes |
| Pre/Post programmable times | Yes | Yes |
| Number of events | Multiple | Multiple |
| Patient Manual Activation | Yes | Yes |
| Silent Recording | Yes | Yes |
A Scott Fetzer, Berkshire Hathaway Company
7
Image /page/7/Picture/0 description: The image shows the logo for ScottCare. The text "ScottCare" is in a large, bold, sans-serif font. Below the name is the text "cardiovascular solutions" in a smaller, sans-serif font. There is a thin line above the text "cardiovascular solutions".
| Features | Predicate Device: TeleSentry
K092947 | New Device: TeleSense* |
|-------------------------------------------------|-----------------------------------------|-------------------------------|
| | | |
| Autotriggering | Yes | Yes |
| Bradycardia | Yes | Yes |
| Tachycardia | Yes | Yes |
| Atrial Fibrillation | Yes | Yes |
| Auto-Trigger On/OFF capability | Yes | Yes |
| Transmission Mode (Bluetooth2.0
SPP Profile) | Yes | Noiii |
| Transmission Mode
(Wi-Fi 802.11 b/g/n) | No | Yesiv |
| RF transmission range | 100 meters open space (Bluetooth) | 100 meters open space (Wi-Fi) |
| Bandwidth | 0.5 - 100 Hz | 0.5-40Hzv |
| Recording Period | 30 days | 30 days |
| Input Impedance | >20 ΜΩ | >20 ΜΩ |
8
Image /page/8/Picture/0 description: The image shows the logo for ScottCare. The text "ScottCare" is in a large, bold, black font. Below the name is the text "cardiovascular solutions" in a smaller, pink font. There is a thin pink line above the text "cardiovascular solutions".
| Features | Predicate Device: TeleSentry
K092947 | New Device: TeleSense* |
|-----------------------------|-----------------------------------------|----------------------------|
| Differential Input | $+/-$ 1mV p-p | $\pm$ 5mV p-pvi |
| Differential Input Range | DC $\pm$ 100mV | DC $\pm$ 300mVvii |
| Common Mode Rejection (CMR) | 92 dB | 80dBviii |
| Common Mode Ratio Range | $+/-$ 1.0 V | $+/-$ 1.0 V |
| Battery type | 3.7V lithium polymer | 3.7V lithium ion |
| Battery Life | 24-36 hours before recharge | 50 hours before rechargeix |
| Relative Humidity | 25% to 95% RH, nc | 25% to 95% RH, nc |
| SPS | 100.200,1000 | 128, 256x |
| Bits | 12 bits | 8,10,12 bitxi |
The Substantial equivalence discussion is further detailed in Volume 12.
*Differences between predicate device and new device are detailed in the endnotes of this document.
Testing Results Summary:
Appropriate testing was conducted in accordance with established design control procedures and regulatory guidance documents. The TeleSense meets the safety, mechanical, electrical, and performance requirements requirements of IEC 60601-1, the emissions requirements of IEC 60601-1-2:2007, and the safety, electrical, and performance requirements of IEC 60601-2-47 Part2.
The internal tests conducted were intended to test the performance of the device and included simulated normal ECG signals and simulated paced ECG signal tests. Data recorded was loaded and analyzed in the HolterCare(K042463) and EventCare (K061780) software. In all tests, the TeleSense produced consistent and acceptable results.
A Scott Fetzer, Berkshire Hathaway Company
9
Image /page/9/Picture/0 description: The image shows the logo for ScottCare. The logo is in black font and the words "cardiovascular solutions" are in a smaller, red font below the main logo. The logo is simple and professional.
Page 7 of 8 ScottCare Corporation P 800.243.9412 4791 West 150th Street F 216.267.6129 Cleveland, Ohio 44135 www.scottcare.com
Conclusion:
The TeleSense and TeleSentry are both intended for diagnostic evaluation of patients who experience transient symptoms or asymptomatic events that may suggest cardiac arrhythmia. The device continuously monitors and records the data, automatically records events triggered by an arrhythmia detection algorithm or manually by the patient, and automatically transmits the recorded event activity associated with these symptoms for review by a licensed physician.
The TeleSense conforms to Good Manufacturing Procedures outlined by the FDA cGMP. This device is safe and effective for the application for which it is intended and has been tested to confirm the safety and efficacy of the device. The TeleSense is found to be substantially equivalent to the TeleSentry.
1 Given the intended diagnostic use, having the 3 channels available from 3 lead provides adequate information in order to obtain the appropriate diagnostic information as required for intended use of the TeleSense is intended to capture tachy, brady, pause, and afib diagnostic data which can be detected from a single channel, and having multiple leads for multiple channels merely provides alternative channels for detection. Therefore, this difference in patient cable has no adverse impact on the safety and effectiveness of the TeleSense relative to the predicate device.
" Given the intended diagnostic use, having the 3 channels provides adequate information in order to obtain the appropriate diagnostic information as required for intended use of the device. The TeleSense is intended to capture tachy, brady, pause, and affb diagnostic data which can be detected from a single channel, and having multiple channels merely provides alternative channels for detection. Therefore, this difference in number of channels has no adverse impact on the safety and effectiveness of the TeleSense relative to the predicate device.
!! The predicate device provided Bluetooth for the purpose of updating device firmware and for device configuration-the same functionality is achieved in the TeleSense through a USB connection.
This does not have an adverse impact on the safety and efficacy of the TeleSense relative to the predicate device. Bluetooth communication is not utilized for any diagnostic purpose; there is no impact on the intended diagnostic use.
" Both the predicate and the TeleSense have the capability to send diagnostic information to a remote server through their respective transmission modes. The transmission mode in TeleSense is more favorable than in the predicate because of Wi-Fi's higher availability. The transmission mode has no adverse effect on the intended diagnostic use, and there are no adverse impacts to the safety and efficacy of the device.
' The TeleSense product's bandwidth exceeds the AAMI/ANSI EC38 standard (which specifies a bandwidth >30Hz), and therefore will not have an adverse impact on the safety and effectiveness of the TeleSense.
11 The specifications and performance of the TeleSense meet those indicated in the EC38 and IEC60601-2-47 standards and therefore will not have an adverse impact on the safety and effectiveness of the TeleSense. The intended diagnostic use if not affected by this specification therefore there is no impact to diagnostic use.
vil The specifications and performance of the TeleSense device meet the established standard EC38 and IEC60601-2-47, and therefore will not have an adverse impact on the safety and effectiveness of the TeleSense relative to the predicate device. The intended diagnostic use if not affected by this specification therefore there is no impact to diagnostic use.
vii The CMR for the new device, TeleSense, differs from the CMR in TeleSentry but still exceeds the specifications in the AAMI/ANSI EC38 and IEC 60601-2-47 standards, and therefore will not have an adverse impact on the intended diagnostics use, safety, nor effectiveness of the TeleSense.
A Scott Fetzer, Berkshire Hathaway Company
10
Image /page/10/Picture/0 description: The image shows the logo for ScottCare. The text "ScottCare" is in a large, bold, sans-serif font. Below the name is the text "cardiovascular solutions" in a smaller, lighter font. The logo is simple and professional, and it is likely used to represent a company that provides cardiovascular solutions.
if The specifications and performance of the TeleSense device exceed those of the predicate device and therefore will not have an adverse impact on the safety and effectiveness of the TeleSense relative to the predicate device. The time before recharge will not have impact on the intended diagnostic use of the device.
- For the intended diagnostic purpose of the device, sampling rates of 128Hz and 256Hz exceeds the adequate sampling rate for capturing sufficient information as limited by the EC38 approved 40Hz bandwidth based on the Nyquist theorem. There is no impact to the intended diagnostic use nor the safety and efficacy of the device.
41 The TeleSense has the same bit settings available as in Telesentry, but also allows for additional sampling rates as well. In this manner, the specifications and performance of the TeleSense device meet or exceed those of the predicate device and therefore will not have an adverse impact on the safety and effectiveness of the TeleSense relative to the predicate device.